É justificável utilizar um segundo ciclo de imunoglobulina para as formas axonais da síndrome de Guillain-Barré?

Translated title of the contribution: Is a second cycle of immunoglobulin justified in axonal forms of Guillain-Barré syndrome?

Daniel Agustin Godoy, Alejandro Rabinstein

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective: In certain situations, severe forms of Guillain-Barré syndrome (GBS) show no response or continue to deteriorate after intravenous immunoglobulin (IVIg) infusion. It is unclear what the best treatment option would be in these circumstances. Method: This is a case report on patients with severe axonal GBS in whom a second cycle of IVIg was used. Results: Three patients on mechanical ventilation who presented axonal variants of GBS, with autonomic dysfunction, bulbar impairment and Erasmus score > 6, showed no improvement after IVIg infusion of 400 mg/kg/d for 5 days. After 6 weeks, we started a second cycle of IVIg using the same doses and regimen as in the previous one. On average, 5 days after the second infusion, all the patients were weaned off mechanical ventilation and showed resolution of their blood pressure and heart rate fluctuations. Conclusions: A second cycle of IVIg may be an option for treating severe forms of GBS.

Original languagePortuguese
Pages (from-to)848-851
Number of pages4
JournalArquivos de Neuro-Psiquiatria
Volume73
Issue number10
DOIs
StatePublished - Jan 1 2015

Fingerprint

Intravenous Immunoglobulins
Immunoglobulins
Artificial Respiration
Intravenous Infusions
Heart Rate
Blood Pressure

Keywords

  • Acute inflammatory demyelinating polyradiculoneuropathy
  • Flaccid acute paralysis
  • Guillain-Barré syndrome
  • Immunoglobulin
  • Immunotherapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Biological Psychiatry

Cite this

É justificável utilizar um segundo ciclo de imunoglobulina para as formas axonais da síndrome de Guillain-Barré? / Godoy, Daniel Agustin; Rabinstein, Alejandro.

In: Arquivos de Neuro-Psiquiatria, Vol. 73, No. 10, 01.01.2015, p. 848-851.

Research output: Contribution to journalArticle

@article{ac4c3753de3d42029f5b58a0920bc086,
title = "{\'E} justific{\'a}vel utilizar um segundo ciclo de imunoglobulina para as formas axonais da s{\'i}ndrome de Guillain-Barr{\'e}?",
abstract = "Objective: In certain situations, severe forms of Guillain-Barr{\'e} syndrome (GBS) show no response or continue to deteriorate after intravenous immunoglobulin (IVIg) infusion. It is unclear what the best treatment option would be in these circumstances. Method: This is a case report on patients with severe axonal GBS in whom a second cycle of IVIg was used. Results: Three patients on mechanical ventilation who presented axonal variants of GBS, with autonomic dysfunction, bulbar impairment and Erasmus score > 6, showed no improvement after IVIg infusion of 400 mg/kg/d for 5 days. After 6 weeks, we started a second cycle of IVIg using the same doses and regimen as in the previous one. On average, 5 days after the second infusion, all the patients were weaned off mechanical ventilation and showed resolution of their blood pressure and heart rate fluctuations. Conclusions: A second cycle of IVIg may be an option for treating severe forms of GBS.",
keywords = "Acute inflammatory demyelinating polyradiculoneuropathy, Flaccid acute paralysis, Guillain-Barr{\'e} syndrome, Immunoglobulin, Immunotherapy",
author = "Godoy, {Daniel Agustin} and Alejandro Rabinstein",
year = "2015",
month = "1",
day = "1",
doi = "10.1590/0004-282X20150136",
language = "Portuguese",
volume = "73",
pages = "848--851",
journal = "Arquivos de Neuro-Psiquiatria",
issn = "0004-282X",
publisher = "Arquivos de Neuro-Psiquiatria",
number = "10",

}

TY - JOUR

T1 - É justificável utilizar um segundo ciclo de imunoglobulina para as formas axonais da síndrome de Guillain-Barré?

AU - Godoy, Daniel Agustin

AU - Rabinstein, Alejandro

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Objective: In certain situations, severe forms of Guillain-Barré syndrome (GBS) show no response or continue to deteriorate after intravenous immunoglobulin (IVIg) infusion. It is unclear what the best treatment option would be in these circumstances. Method: This is a case report on patients with severe axonal GBS in whom a second cycle of IVIg was used. Results: Three patients on mechanical ventilation who presented axonal variants of GBS, with autonomic dysfunction, bulbar impairment and Erasmus score > 6, showed no improvement after IVIg infusion of 400 mg/kg/d for 5 days. After 6 weeks, we started a second cycle of IVIg using the same doses and regimen as in the previous one. On average, 5 days after the second infusion, all the patients were weaned off mechanical ventilation and showed resolution of their blood pressure and heart rate fluctuations. Conclusions: A second cycle of IVIg may be an option for treating severe forms of GBS.

AB - Objective: In certain situations, severe forms of Guillain-Barré syndrome (GBS) show no response or continue to deteriorate after intravenous immunoglobulin (IVIg) infusion. It is unclear what the best treatment option would be in these circumstances. Method: This is a case report on patients with severe axonal GBS in whom a second cycle of IVIg was used. Results: Three patients on mechanical ventilation who presented axonal variants of GBS, with autonomic dysfunction, bulbar impairment and Erasmus score > 6, showed no improvement after IVIg infusion of 400 mg/kg/d for 5 days. After 6 weeks, we started a second cycle of IVIg using the same doses and regimen as in the previous one. On average, 5 days after the second infusion, all the patients were weaned off mechanical ventilation and showed resolution of their blood pressure and heart rate fluctuations. Conclusions: A second cycle of IVIg may be an option for treating severe forms of GBS.

KW - Acute inflammatory demyelinating polyradiculoneuropathy

KW - Flaccid acute paralysis

KW - Guillain-Barré syndrome

KW - Immunoglobulin

KW - Immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=84943787927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943787927&partnerID=8YFLogxK

U2 - 10.1590/0004-282X20150136

DO - 10.1590/0004-282X20150136

M3 - Article

VL - 73

SP - 848

EP - 851

JO - Arquivos de Neuro-Psiquiatria

JF - Arquivos de Neuro-Psiquiatria

SN - 0004-282X

IS - 10

ER -